Brief: NexImmune Reports Q2 2022 Results And Highlights FDA Clearance Of IND For NEXI-003 For Treatment Of HPV-Related Cancers

Neximmune

15/08/2022 22:04

Aug 15 (Reuters) - NexImmune Inc  NEXI.O :
    * NEXIMMUNE REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
AND
HIGHLIGHTS FDA CLEARANCE OF IND FOR NEXI-003 FOR THE TREATMENT
OF HPV-RELATED CANCERS
    * NEXIMMUNE INC - QTRLY LOSS PER SHARE $0.69
    * NEXIMMUNE INC - QTRLY CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES WERE $53.1 MILLION
    * NEXIMMUNE INC - PLANS TO REPORT ADDITIONAL PRECLINICAL AND
IND
ENABLING DATA FOR AIM INJECTABLE PLATFORM IN 2H22

Source text for Eikon:  ID:nGNX1Q14z5 
Further company coverage:  NEXI.O 

 ((Reuters.Briefs@thomsonreuters.com;))